Welcome to our dedicated page for OS THERAPIES INCORPORATED SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OS Therapies Incorporated (OSTX) SEC filings page on Stock Titan brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a primary source view of its clinical-stage oncology business. As a NYSE American–listed emerging growth company, OS Therapies uses current reports on Form 8-K, registration statements, and proxy materials to describe its listeria-based cancer immunotherapy programs, ADC and drug conjugate platform, capital structure, and governance decisions.
Investors can use this page to access Form 8-K filings that detail material events such as warrant exercise inducement and exchange offers, gross proceeds from warrant exercises, and the terms of new warrants issued to accredited investors. These filings explain how OS Therapies raises capital to support regulatory submissions and commercial preparation for its lead asset OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and to fund preparations for the proposed spin-off of its veterinary subsidiary, OS Animal Health.
Other 8-Ks and the company’s definitive proxy statement on Schedule 14A provide insight into corporate governance, including amendments to the certificate of incorporation to increase authorized common stock, changes to the 2023 Incentive Compensation Plan, quorum requirements under the bylaws, and shareholder approvals related to potential share issuances and a shareholder rights agreement. Registration statements on Form S-1 and Form S-3 describe the resale of shares underlying warrants, the company’s status as a smaller reporting company and emerging growth company, and the use of proceeds from warrant exercises.
Through Stock Titan, these filings are updated in near real time from EDGAR and are paired with AI-powered summaries that translate legal and financial language into plain English. Users can quickly understand the key points of complex documents, such as how a warrant inducement affects dilution, what changes a bylaw amendment introduces, or how a registration statement relates to existing warrants. Over time, this filings archive helps investors follow OS Therapies’ progress as it advances OST-HER2 through the regulatory process, develops its tunable ADC (tADC) platform, and executes on planned transactions like the OS Animal Health spin-off.
OS Therapies Incorporated entered into warrant inducement offer letters with fewer than 10 accredited investors holding existing warrants to purchase up to 5,382,148 shares of common stock. The investors agreed to exercise these existing warrants for cash at a reduced exercise price of $1.40 per share, and in return the company will issue new warrants to purchase up to 5,382,148 additional shares at the same exercise price, exercisable immediately for five years.
The company engaged an SEC-registered broker-dealer as exclusive solicitation agent and expects aggregate gross proceeds of approximately $7.5 million, before an 8.0% cash fee to the agent and up to $25,000 of expenses. OS Therapies plans to use the net proceeds to support U.S. and international regulatory and pre-commercial efforts for OST-HER2 in osteosarcoma, to help fund spinoff preparations for its OS Animal Health subsidiary, and for general corporate purposes.
The new warrants include beneficial ownership caps of 4.99% or, at the holder’s election, 9.99%, a potential forced exercise feature if the stock trades at or above 300% of the exercise price for 20 consecutive trading days, and a cashless exercise option if a resale registration statement is not effective. The company agreed to file a resale registration statement for shares issuable upon exercise of the new warrants within 30 days of closing.
OS Therapies Inc. director reports new stock option grant and holdings. Theodore F. Search, a director of OS Therapies Inc., reported receiving stock options on 10/21/2025 to buy 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as he is still serving as a director on that date, and expire on 10/21/2035.
After this grant, he beneficially owns 140,000 stock options directly. He also reports beneficial ownership of 20,000 common shares directly and 435,835 common shares indirectly through Mill River Partners LLC, where he serves on the board of managers and shares voting and investment power.
OS Therapies Inc. filed a report showing that senior officer Robert Petit, the company’s Chief Medical Officer and Chief Scientific Officer, received a new equity award. On October 21, 2025, he was granted stock options to purchase 500,000 shares of OS Therapies common stock at an exercise price of $1.80 per share.
The options are scheduled to vest in full on the one-year anniversary of the grant date, as long as he is still employed by OS Therapies at that time. After this transaction, Petit also holds 200,000 shares of OS Therapies common stock directly, in addition to the newly granted options.
OS Therapies Inc. reported an insider equity award for its President and CEO, who is also a director. On October 21, 2025, the executive received stock options to purchase 1,950,000 shares of OS Therapies common stock at an exercise price of $1.8 per share. These options expire on October 21, 2035 and vest in full on the one-year anniversary of the grant date, as long as the executive remains employed by the company on that date.
Following this grant, the reporting person holds 2,473,000 shares of common stock directly, in addition to the newly granted 1,950,000 stock options, reflecting a significant personal equity stake in OS Therapies.
OS Therapies Inc director reports stock option grant. A director of OS Therapies Inc (OSTX) reported receiving stock options to purchase 140,000 shares of the company’s common stock on October 21, 2025, at an exercise price of $1.80 per share. The options vest in full on the one-year anniversary of the grant date, as long as the director is still serving on the board at that time, and are scheduled to expire on October 21, 2035.
OS Therapies Inc. director receives new stock option grant. A reporting person serving as a director of OS Therapies Inc. (ticker OSTX) was granted stock options on October 21, 2025 to purchase 140,000 shares of the company’s common stock at an exercise price of
OS Therapies Inc director reports new stock option grant and holdings. On October 21, 2025, director John Ciccio was granted stock options to buy 140,000 shares of OS Therapies Inc common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, if he is still serving as a director on that date, and expire on October 21, 2035.
After the reported transactions, he beneficially owns 435,835 shares of common stock indirectly through Mill River Partners LLC and 20,000 shares directly, in addition to the 140,000 stock options held directly.
OS Therapies Inc. reported that its Chief Financial Officer received a new stock option grant. On October 21, 2025, the reporting person was granted options to purchase 200,000 shares of OS Therapies common stock at an exercise price of $1.8 per share, under a stock option award agreement.
The options vest in full on the one-year anniversary of the grant date, as long as the individual is still serving as an employee on that date. Following this grant, the reporting person holds 109,375 shares of common stock directly and 200,000 stock options directly.
OS Therapies Inc director Avril McKean-Dieser reported new equity awards and current holdings. As of the reported transactions, the director beneficially owns 5,000 shares of OS Therapies common stock in direct ownership. On October 21, 2025, the director was granted stock options to purchase 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, provided the director is still serving on the board at that time, and expire on October 21, 2035. The grant reflects part of the director’s equity-based compensation.
OS Therapies (OSTX) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $6.9 million for the quarter and $15.3 million year‑to‑date, driven by higher research and development ($7.6 million YTD) and general and administrative expenses ($9.2 million YTD). Cash was $1.88 million, and management stated these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
Total assets rose to $9.0 million, reflecting the April acquisition of HER2 immuno‑oncology assets from Ayala, recorded at a fair value of $6.86 million, largely paid in common stock. The company recognized $236 thousand of amortization on these intangibles year‑to‑date. Stockholders’ equity improved to $3.64 million from a deficit at year‑end 2024, aided by conversions of preferred stock and warrant activity.
Operating cash burn was $10.5 million YTD, partly offset by $7.3 million in financing cash inflows, including warrant exercises and a preferred stock raise. The warrant liability declined to $0 with a $1.42 million favorable fair value change. Shares outstanding were 35,214,352 as of November 14, 2025.